Everything below concerns RP-HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-27. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
=== Transitional period (2012–14) === The Yemeni Revolution came to an apparently successful conclusion in 2012 for the opposition, as Saleh left office. However, unrest continued in both northern and southern Yemen.
=== Sleep === Preliminary research indicates that ghrelin participates in the regulation of circadian rhythms. A review reported finding strong evidence that sleep restriction affected ghrelin or leptin levels, or energy expenditure.
== Side effects == Eflornithine is not genotoxic; no tumour-inducing effects have been observed in carcinogenicity studies, including one photocarcinogenicity study. No teratogenic effects have been detected.
===== Sixth generation ===== Sixth generation breast implants were introduced in the early 2010s to address some of the issues seen in previous generations. They feature a smoother surface that is designed to minimize the body's inflammatory response and reduce the risk of a foreign body reaction. These implants use a newer, biomimetic topography that helps to reduce bacterial growth and inflammation compared to the earlier macro-textured devices. Additionally, they incorporate other advancements, such as ergonomic gels that change shape depending on body position and advanced multi-layered shells to reduce the diffusion of silicone. Some manufacturers have also introduced lightweight alternatives that use hollow microspheres mixed with silicone gel to make the implants lighter for a given volume. This has led to improved results, with studies showing that the implants form thinner capsules and cause less inflammation than their predecessors.
Sources: en.wikipedia.org
== External links == Psilocybin - Isomer Design Psilocin - PsychonautWiki Psilocybin mushrooms - PsychonautWiki Psilocybin & Psilocin - Erowid 4-HO-DMT (Psilocybin) - TiHKAL - Erowid 4-HO-DMT (Psilocybin) - TiHKAL - Isomer Design The Big & Dandy 4-HO-DMT Thread - Bluelight Psilocybin Investigator's Brochure, Version 4.1 (2021) - Usona Institute
== Reaction mechanism == The nucleophilic attack on the carbonyl group proceeds via the Bürgi-Dunitz trajectory. The angle between the line of nucleophilic attack and the C-O bond is greater than 90˚ due to a better orbital overlap between the HOMO of the nucleophile and the π* LUMO of the C-O double bond.
{\displaystyle {\begin{aligned}u_{x}&={\frac {4{\sqrt {2}}}{3{\sqrt {3}}}}\,U_{0}\left[\,\sin \left(kx-{\frac {\pi }{3}}\right)\cos \left(ky+{\frac {\pi }{3}}\right)\sin \left(kz+{\frac {\pi }{2}}\right)-\cos \left(kz-{\frac {\pi }{3}}\right)\sin \left(kx+{\frac {\pi }{3}}\right)\sin \left(ky+{\frac {\pi }{2}}\right)\,\right]e^{-3\nu k^{2}t}\\u_{y}&={\frac {4{\sqrt {2}}}{3{\sqrt {3}}}}\,U_{0}\left[\,\sin \left(ky-{\frac {\pi }{3}}\right)\cos \left(kz+{\frac {\pi }{3}}\right)\sin \left(kx+{\frac {\pi }{2}}\right)-\cos \left(kx-{\frac {\pi }{3}}\right)\sin \left(ky+{\frac {\pi }{3}}\right)\sin \left(kz+{\frac {\pi }{2}}\right)\,\right]e^{-3\nu k^{2}t}\\u_{z}&={\frac {4{\sqrt {2}}}{3{\sqrt {3}}}}\,U_{0}\left[\,\sin \left(kz-{\frac {\pi }{3}}\right)\cos \left(kx+{\frac {\pi }{3}}\right)\sin \left(ky+{\frac {\pi }{2}}\right)-\cos \left(ky-{\frac {\pi }{3}}\right)\sin \left(kz+{\frac {\pi }{3}}\right)\sin \left(kx+{\frac {\pi }{2}}\right)\,\right]e^{-3\nu k^{2}t}\end{aligned}}}
== Objectives == Gemini 4 would be the first multi-day space flight by the United States, designed to show that it was possible for humans to remain in space for extended lengths of time. The four-day, 66-orbit flight would approach but not break the five-day record set by the Soviet Vostok 5 in June 1963. Subsequent Gemini flights would be longer, to prove endurance exceeding the time required to fly to the Moon and back. A second objective was the first American extra-vehicular activity (EVA), known popularly as a "space walk". The first space walk had already been performed by Soviet Alexei Leonov on Voskhod 2 in March 1965. NASA moved up the spacewalk from the original schedule, to demonstrate that the US was gaining on the early lead taken by the Soviets in what was known as the Space Race. As late as 11 days before the scheduled June 3 launch, newspapers were reporting NASA saying that it "had not yet determined whether White would be the first American astronaut to expose himself to the elements of space" and that "A decision might not be made until a day or two before launching." A third objective was for Gemini 4 to attempt the first space rendezvous, flying in formation with the spent second stage of its Titan II launch vehicle.
Itopride increases acetylcholine concentrations by inhibiting dopamine D2 receptors and acetylcholinesterase. Higher acetylcholine increases GI peristalsis, increases the lower esophageal sphincter pressure, stimulates gastric motility, accelerates gastric emptying, and improves gastro-duodenal coordination. Itopride given as a single dose study found that it also raises levels of motilin, somatostatin and lowers levels of cholecystokinin, as well as adrenocorticotropic hormone. These effects may also contribute to itopride's pharmacology.
Sources: en.wikipedia.org
=== Traditional medicine and research === The bark, sap, roots, leaves, seeds, and flowers are used in traditional medicine. Research has examined how it might affect blood lipid profiles and insulin secretion. Extracts from leaves contain various polyphenols, which are under basic research to determine their potential effects in humans. Despite considerable preliminary research to determine if moringa components have bioactive properties, no high-quality evidence has been found to indicate that it has any effect on health or diseases.
==== Noncanonical pathways ==== The noncanonical planar cell polarity (PCP) pathway does not involve β-catenin. It does not use LRP-5/6 as its co-receptor and is thought to use NRH1, Ryk, PTK7 or ROR2. The PCP pathway is activated via the binding of Wnt to Fz and its co-receptor. The receptor then recruits Dsh, which uses its PDZ and DIX domains to form a complex with Dishevelled-associated activator of morphogenesis 1 (DAAM1). Daam1 then activates the small G-protein Rho through a guanine exchange factor. Rho activates Rho-associated kinase (ROCK), which is one of the major regulators of the cytoskeleton. Dsh also forms a complex with rac1 and mediates profilin binding to actin. Rac1 activates JNK and can also lead to actin polymerization. Profilin binding to actin can result in restructuring of the cytoskeleton and gastrulation.
=== Operation Iraqi Freedom, 2006–2009, "The Surge" === In December 2006, 2nd BCT deployed once again to Iraq in support of OIF. On 4 January 2007, 2nd Brigade deployed to northern Bagdad in the Sumer and Talbiyah district, returning 8 March 2008. On 4 June 2007, 1st Brigade deployed to Southern Iraq, returning 15 July 2008. Since the deployment began, the division has lost 37 paratroopers. Since 11 September 2001, the division has lost 20 paratroopers in Afghanistan and 101 paratroopers in Iraq.
=== Monitoring of activists === The Stratfor email leak revealed that Dow Chemical had engaged Stratfor to spy on the public and personal lives of activists involved in the Bhopal disaster, including the Yes Men. E-mails to Dow representatives from hired security analysts list the YouTube videos liked, Twitter and Facebook posts made and the public appearances of these activists. Journalists, filmmakers and authors who were investigating Bhopal and covering the issue of ongoing contamination, such as Jack Laurenson and Max Carlson, were also placed under surveillance. Stratfor released a statement condemning the revelation by Wikileaks while neither confirming nor denying the accuracy of the reports and would only state that it had acted within the bounds of the law. Dow Chemical also refrained from commenting on the matter. Ingrid Eckerman, a member of the International Medical Commission on Bhopal, has been denied a visa to visit India.
Ubiquitin is a small protein that exists in all eukaryotic cells. It performs its myriad functions through conjugation to a large range of target proteins. A variety of different modifications can occur. The ubiquitin protein itself consists of 76 amino acids and has a molecular mass of about 8.6 kDa. Key features include its C-terminal tail and the 7 lysine residues. It is highly conserved throughout eukaryote evolution; human and yeast ubiquitin share 96% sequence identity. Moreover, human and yeast ubiquitin share two conserved salt bridges, K11–E34 and K27–D52, which are critical for protein stability and function.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.